Conference Correspondent
News, views, and coverage of important topics and discussions from oncology conferences and events.
Dual immunotherapy provides significant and durable benefits as first-line treatment and as neoadjuvant therapy in advanced melanoma. Read More ›
MRD status at the time of allogeneic stem-cell transplantation and the number of remissions prior to transplant were shown to be important independent prognostic factors in patients with AML. Read More ›
Addition of venetoclax to FLAG-IDA yielded high minimal residual disease–negative composite complete response rates in newly diagnosed patients with AML, accompanied by a favorable safety profile. Read More ›
The phase 3 AGILE study demonstrated that ivosidenib + azacitidine therapy provided significant survival benefit compared with placebo plus azacitidine in patients with newly diagnosed IDH1 mutation–positive AML who were ineligible for intensive chemotherapy. Read More ›
AML patients who underwent allogeneic stem-cell transplantation from unrelated donors while in their second complete remission with post-transplant cyclophosphamide had similar outcomes to those who underwent transplantation while in first complete remission. Read More ›
In the first-in-human phase 1/2 AUGMENT 101 study, SNDX-5613 demonstrated an acceptable safety profile and promising antileukemic activity in patients with heavily pretreated relapsed/refractory MLL-rearranged and NPM1-mutated acute leukemias. Read More ›
Patients with essential thrombocythemia and myelofibrosis enroll in various studies in both academic and community centers across the United States. The comparison of patient characteristics across these centers may provide valuable insight into the management of these myeloproliferative neoplasms. Read More ›
Thrombus formation in patients with myelofibrosis is a common marker of disease progression. The relationship between IPSS score and JAK mutation status may distinguish patients at high risk for thrombosis, which may serve as a guide to therapy decisions. Read More ›
JAK inhibitors are approved in myelofibrosis for relief of symptoms and improvement in spleen responses but have not been shown to impact disease progression. Tagraxofusp monotherapy holds promise for treating myelofibrosis patients who are refractory to JAK inhibitors based on early clinical data. Read More ›
TGFβ is a cytokine that enhances myelofibrosis disease progression. AVID200, a TGFβ1/3 inhibitor, may provide clinical benefit manifesting as improved platelet counts in patients with myelofibrosis who have thrombocytopenia. Read More ›